Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.

doi:10.1002/hep.21800

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.

Hepatology (Baltimore, Md.) - 1 Oct 2007

Yoo Byung Chul, Kim Ju Hyun, Kim Tae-Hun, Koh Kwang Cheol, Um Soon-Ho, Kim Young Soo, Lee Kwan Sik, Han Byung Hoon, Chon Chae Yoon, Han Joon-Yeol, Ryu Soo Hyung, Kim Haak Cheoul, Byun Kwan Soo, Hwang Seong Gyu, Kim Byung-Ik, Cho Mong, Yoo Kwon, Lee Heon-Ju, Hwang Jae Seok, Kim Yun Soo, Lee Young-Suk, Choi Sung-Kyu, Lee Youn-Jae, Yang Jin-Mo, Park Joong-Won, Lee Myung-Seok, Kim Dae-Ghon, Chung Young-Hwa, Cho Se-Hyun, Choi Jong-Young, Kweon Young-Oh, Lee Heon Young, Jeong Sook-Hyang, Yoo Hee-Won, Lee Hyo-Suk

Abstract excerpt

UNLABELLED: Clevudine is a pyrimidine analog with potent and sustained antiviral activity against HBV. In the present study, we evaluated the safety and efficacy of clevudine 30 mg daily for 24 weeks and assessed the durability of antiviral response for 24 weeks after cessation of dosing in hepat...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiviral Agents

Share to Dose-Response Relationship, Drug

Share to Double-Blind Method

Share to Drug Resistance, Viral

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Source

Open in PubMed

Identifiers

PMID: 17647293
DOI: 10.1002/hep.21800

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17647293-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.PMID 17647293Read ↗

Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.Semantic proximity Read ↗

Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study.Semantic proximity Read ↗

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.Semantic proximity Read ↗

Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B.Semantic proximity Read ↗

Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study.Semantic proximity Read ↗

Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B.Semantic proximity Read ↗

[Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases].Semantic proximity Read ↗

Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.Semantic proximity Read ↗

Identification and Characterization of Clevudine-Resistant Mutants of Hepatitis B Virus Isolated from Chronic Hepatitis B PatientsSemantic proximity Read ↗

Clevudine: a potent inhibitor of hepatitis B virus<i>in vitro</i>and<i>in vivo</i>Semantic proximity Read ↗

Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.Semantic proximity Read ↗

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.